Porcupine Is Not Required for the Production of the Majority of Wnts from Primary Human Astrocytes and CD8+ T Cells

Maureen H. Richards, Melanie S. Seaton, Jennilee Wallace, Lena Al-Harthi
Department of Immunology/Microbiology, Rush University Medical Center, Chicago, Illinois, United States of America

Abstract

Wnts are small secreted glycoproteins that are highly conserved among species. To date, 19 Wnts have been described, which initiate a signal transduction cascade that is either β-catenin dependent or independent, culminating in the regulation of hundreds of target genes. Extracellular release of Wnts is dependent on lipidation of Wnts by porcupine, a membrane-bound-O-acyltransferase protein in the endoplasmic reticulum. Studies demonstrating the requirement of porcupine for Wnts production are based on cell line and non-human primary cells. We evaluated the requirement for porcupine for Wnts production in human primary astrocytes and CD8+ T cells. Using IWP-2, an inhibitor of porcupine, or siRNA targeting porcupine, we demonstrate that porcupine is not required for the release of Wnt 1, 3, 5b, 6, 7a, 9a, 9b, and 10a. While IWP had no effect on Wnt 2b release, knockdown of porcupine by siRNA reduced Wnt 2b release by 60%. These data indicate that porcupine-mediated production of Wnts is context dependent and is not required for all Wnts production, suggesting that alternative mechanisms exist for Wnts production.

Citation: Richards MH, Seaton MS, Wallace J, Al-Harthi L (2014) Porcupine Is Not Required for the Production of the Majority of Wnts from Primary Human Astrocytes and CD8+ T Cells. PLoS ONE 9(3): e92159. doi:10.1371/journal.pone.0092159

Competing Interests: The authors have declared that no competing interests exist.

E-mail: Lena_Al-Harthi@rush.edu

Introduction

Wnts are evolutionarily conserved small glycoproteins that initiate the Wnt signaling transduction cascade. The Wnt pathway is involved in many cellular processes including development, proliferation, survival, regeneration, wound healing, and stress responses [1–3]. It is initiated by binding of Wnts to frizzled receptors (Fz) initiating either the β-catenin-dependent or β-catenin-independent (calmodulin/Ca2+ and planar polarity) pathway of signal transduction, which culminates in target gene regulation [1, 3]. To date, nineteen Wnts are described in mammals, which are Wnt 1, Wnt 2, Wnt 2b, Wnt 3, Wnt 3a, Wnt 4, Wnt 5a, Wnt 5b, Wnt 6, Wnt 7a, Wnt8a, Wnt 9a, Wnt 9b, Wnt 10a, and Wnt 10b, Wnt 11, and Wnt 16. Wnts are translated and targeted into the endoplasmic reticulum (ER) where they are bound and modified with lipids by the membrane-bound O-acyltransferase Porcupine [4]. Porcupine is an eight transmembrane spanning protein with a carboxy-terminal tail ending within the bilayer of the ER membrane [5]. Porcupine catalyzes the palmitoylation of Wnts which facilitates their secretion to become functionally active. In mice, Wnt3a porcupine allows for lipidation at the cysteine 77 and serine 209 [6, 7]. The lipidated Wnts are then transported to the Golgi where they are bound by the transmembrane protein Wntless. Wntless then shuttles the Wnts to the plasma membrane where they are eventually released into the extracellular space [7]. Findings in mouse and Drosophila, indicate that Wnts require lipidation by porcupine in order to be recognized by WLS [8, 9].

In a seminal paper by Chen et al, small molecule inhibitors of Wnts production were identified using a high stringency cell-based screening strategy in mouse L-cells that stably express the TOPFlash construct, a plasmid containing putative TCF/LEF binding sites linked to the firefly luciferase reporter gene. TOPFlash activity is an indicator of Wnt/β-catenin activity [10]. Five compounds termed Inhibitors of Wnt Response (IWR) and four compounds termed Inhibitors of Wnt Production (IWP) were identified. Recent published work by the same group has identified an additional 13 IWP compounds [11]. In the original work, they showed that IWP compounds were capable of inhibiting TOPFlash activity in response to Wnt1 and Wnt2. IWP-2 was found to block several Wnt-dependent processes including, phosphorylation of LRP5/6, phosphorylation of disheveled2, and accumulation of β-catenin in mouse- L cells. This was not Wnt3a specific as levels of lipidated Wnt5a were also decreased in IWP-2 treated cells. IWP-2 mediates its effect through inhibition of porcupine [10]. If porcupine was overexpressed in IWP-2 treated cells, then lipidation levels were returned to normal levels. L-Wnt3a cells treated with IWP-2 still secreted Wnts but they were not functional as they lacked palmitoylation. In addition, IWP-2 does not alter localization of porcupine to the ER or induce destruction of porcupine indicating that IWP either inhibits the porcupine active site or regulates porcupine [10]. These studies identified IWP-2 as an inhibitor of Wnt production, which is a valuable tool for studies requiring inhibition of Wnts. The consensus is that porcupine is required for Wnt production.
Because many of the studies detailing the complex process of Wnts production are largely based on human cell lines, drosophila, zebra fish, and mice, we evaluated the requirement for porcupine in Wnts production and efficacy of IWP-2 to inhibit Wnt production and activity in human primary-progenitor-derived astrocytes (PDAs), Human Fetal Astrocytes (HFA), a human astrocytic cell line (U138), and primary human CD8+ T cells. We demonstrate that IWP-2 does not inhibit Wnt production in these cells and that knockdown for porcupine does not alter the majority of Wnts production, except for Wnt2b. These findings are significant because they indicate that requirement for porcupine for Wnt production is context dependent and also depends on the type of Wnt in question. Most importantly, pharmacological inhibitors of porcupine may not be an effective strategy to block Wnt release in human cells.

Materials and Methods

Ethics Statement

Research involving human subjects was conducted in accordance with institutional and U.S. government guidelines on human research. The study was approved by Rush Institutional Review Board (IRB) under protocol number L06090703-CRO1. All donors signed a consent form and a HIPPA form to allow for blood draw. The signed documents were kept in a binder in the lab. The study was performed without identifying the blood donors.

Culture of Human PDAs, HFAs, U138s, and L-Wnt3a Cells

Human fetal astrocytes (HFA), isolated at approximately 20 weeks of gestation, were purchased from Lonza (Lonza Biologics, Portsmouth, NH). U138MG cells were obtained from ATCC (ATCC HTB-16, Manassas VA) and cultured as described in ([12]). Human Progenitor-Derived Astrocytes (PDA) were generated from neural progenitor cells, as previously described ([13]). Briefly, progenitor cells were provided by Dr. Eugene Major (National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD (NIH) and seeded on poly-D-lysine-coated T-75 tissue culture flasks at 2 x 10^6 cells/flask. Cells were maintained in progenitor medium consisting of neurobasal media (Life Technologies Invitrogen, Carlsbad, CA) supplemented with 0.5% bovine albumin (Sigma, St. Louis, MO), neurosurvival factor (Lonza), N2 components (Life Technologies Invitrogen), 25 ng/ml fibroblast growth factor, 20 ng/ml epidermal growth factor (R&D Systems, Minneapolis MN), 50 μg/ml gentamicin (Lonza) and 2 mM L-glutamine (Life Technologies Invitrogen). To induce differentiation, progenitor medium was replaced with PDA medium containing DMEM (Life Technologies Invitrogen) supplemented with 10% heat-inactivated FBS (Sigma), 2 mM L-glutamine, and 50 μg/ml gentamicin. L-Wnt3a (ATCC CRL-2647) were cultured in complete DMEM with 0.4 mg/ml G-418. Media was supplemented every three days.

Culture and Activation of Human Peripheral Blood Mononuclear Cells (PBMCs) and Isolation of CD8+ T cells

PBMCs were isolated from venous blood of healthy donors using lymphocyte separation medium (Lonza Biologies, Portsmouth, NH) and density centrifugation. PBMCs were then cultured at 1 x 10^5 cells mL of RPMI 1640, 10% heat-inactivated fetal bovine serum (FBS), 200 mM L-glutamine, and 1% penicillin/streptomycin (Lonza Biologies, Portsmouth, NH). Cells were activated with 1 μg/mL anti-CD3/anti-CD28 antibodies (BD Biosciences, San Jose, CA) and 100 units of recombinant human IL-2 (AIDS reagent program, Germantown, MD) for three days. In some cases CD8+ T cells were further isolated from PBMCs. CD8+ T cells were isolated using an untouched CD8+ T cell Isolation Kit (Miltenyi Biotec, Germany) on an AutoMACS Separator (Miltenyi Biotec, Germany). CD8+ T cells were cultured for three days with 1 μg/mL anti-CD3/anti-CD28 antibodies (BD Biosciences, San Jose, CA) and 100 units of recombinant human IL-2 (AIDS reagent program) at 1 x 10^6 cells/mL of RPMI 1640. In some experiments, cells were stained with carboxyfluorescein succinimidyl ester (CFSE, Invitrogen Life Technologies) prior to culture and treatment with 5 μM IWP-2. Three days later, cells were run on a BD FACSVerse flow cytometer (BD Biosciences) to determine percentage of proliferating cells.

Transfection with TOPFlash and Dual Luciferase Assay

To measure β-catenin-dependent signaling activity, 5 x 10^6 PBMCs cells were transfected with 10 μg TOPFlash reporter construct (Millipore, Billerica, MA) or FOPFlash and renilla plasmid using the Amxara nucleofection protocol (Amxara, Gaithersburg, MD), as recommended by the manufacturer. PDA and L-Wnt3a cells were transfected with 5 μg TOPFlash reporter construct or FOPFlash and renilla plasmid using Lipofectamine (Life Technologies Invitrogen) according to manufacturer’s instructions. Three days later, construct reporter activity was performed using a dual-luciferase reporter assay using 10 to 20 μl of lysate (Promega, Madison, WI). Briefly, the Relative Light Units (RLUs) were normalized to a Renilla luciferase control or μg/ml of protein as indicated. The total protein concentration was measured using a Pierce bicinchoninic acid (BCA) protein assay kit (Thermo Scientific, Waltham, MA).

siRNA Knockdown of Porcupine

PDAs and U138s were transfected with On-Target plus Smartpool siRNAs (Thermo Scientific) specific for porcupine or scrambled siRNA using Lipofectamine siRNAmax according to the manufacturer’s protocol (Life Technologies Invitrogen). The cells were approximately 60 to 70% confluent at the time of transfection. Efficiency of transfection was confirmed at 48 hours by qRT-PCR and by western blot at 72 and 96 hours.

Western Blot for Porcupine, Wnt 1, 2b, 3, 5b, 10b and 6, 10a, and 16

Porcupine antibody was purchased from Millipore (Billerica, MA) and all Wnts antibodies were purchased from Abcam (Cambridge, MA). Western blotting was performed according to a standard protocol at the following concentrations of antibodies: Porcupine clone 15G12.1 at 1:1000, Wnt 1 clone ab15251 at 1:500, Wnt2b clone ab50575 1:1000, Wnt3 clone ab32249 at 1:500, Wnt5b clone ab70816 at 1:500, Wnt6 clone ab50503 at 1:200, Wnt7a clone ab100792 at 1:500, Wnt10a clone ab97469 at 1:1000, and Wnt16 clone ab64461 at 1:1000. Secondary antibody conjugated to horseradish peroxidase (HRP) at 1:50,000 (Cell Signal Technology) was used. The membranes were developed with SuperSignal West Femto maximum-sensitivity substrate (Thermo Sciences).

Statistics

Comparisons between groups were analyzed using unpaired Student’s t test. p values less that 0.05 were considered significant. All error bars are representative of standard deviation within the sample group. Experiments were repeated at least three times.
Results

Previous studies indicated that porcupine is required for Wnt production in drosophila, mouse, and human cells including HEK293, mouse fibroblast L cells, and NIH3T3 cells [1]. To determine whether this requirement is context dependent, we evaluated the efficacy of IWP-2 in inhibiting Wnt production in human primary astrocyte and CD8+ T cells. Firstly, we transfected L-Wnt3a cells with a Wnt/β-catenin pathway responsive firefly luciferase reporter plasmid (TOPflash) prior to treatment with IWP-2 vehicle (10 μM DMSO), 5 μM IWP-2, or 10 μM IWP-2. Consistent with data published by Chen et al., IWP-2 treatment inhibited Wnt mediated β-catenin activity by 60% in 5 μM IWP-2 and 40% in 10 μM IWP-2 (Fig. 1A) [10]. As 5 μM IWP-2 was better able to reduce β-catenin activity and 5 μM was the dose utilized in previous publications this is the dose we utilized in our studies.

Human astrocytes express significant level of endogenous Wnt/β-catenin activity and as such they are an ideal tool to study Wnts production in a system that does not rely on artificial over expression of Wnts [14,15]. PDAs release Wnt 1, 2b, 3, 5b, and 10b (Fig. 2A–E). To assess whether IWP-2 can inhibit Wnts production, we treated PDAs with 5 μM of IWP-2 every day for three days. The supernatant was replaced after the first day and cells were re-treated with IWP-2 to allow for accumulation of Wnts. Twenty-four hours after the last IWP-2 treatment, supernatant was collected and a western blot was performed to detect secreted Wnts (Fig. 2A–E). Treatment with IWP-2 did not inhibit production of Wnt 1 (Fig. 2A), 2b (Fig. 2B), 3 (Fig. 2C), 5b (Fig. 2D), or 10b (Fig. 2E). These data indicate that IWP-2 did not alter Wnt levels as evaluated by WB.

To assess whether the inability of IWP-2 to inhibit Wnt production is astrocyte-specific, we evaluated the impact of IWP-2 on Wnts production in primary human CD8+ T cells. CD8+ T cells secrete Wnts 1, 3, 6, 7a, 10a, and 16 (Fig. 3A–F). CD8+ T cells were activated by anti-CD3/CD28 co-stimulation and treated with 5 μM IWP-2 for three days. After the third day the supernatant was collected and assessed for Wnt protein. IWP-2 treatment of CD8+ T cells did not alter the expression of any of the Wnts (Fig. 3A–F). These data demonstrate that IWP-2 treatment does not inhibit production of Wnts in two human primary cell types, astrocytes and CD8+ T cells.

Chen et al previously showed that IWP-2 inhibited Wnt production and function through inhibition of porcupine [10]. Porcupine is responsible for lipidation of Wnts in the endoplasmic reticulum allowing for Wnts to bind Wntless and be transported from the Golgi to the plasma membrane [7]. Other studies have shown that acylation by porcupine is necessary for Wnt function after production as genetic deletion of porcupine is embryonic lethal [5,16–20]. For example, if the Cys77 loci is not acylated in Wnt3a it is unable to bind frizzled and has reduced signaling activity [21]. To determine whether porcupine is important for Wnts to function in primary human cells, we transfected human PBMCs with TOPflash, treated the cells with supernatant from IWP-2 treated human fetal astrocytes (e.g. astrocyte conditioned media/ACM), and measured TOPflash activity in PBMCs 3 days post-treatment. We found that ACM induced β-catenin signaling in PBMCs by 2.5-fold regardless of whether the ACM was from Hfas treated with IWP-2 or vehicle (DMSO) (Fig. 4). These data confirm that IWP-2 treatment does not inhibit Wnt ligand secretion or function, as these Wnts can in turn induce β-catenin-mediated signaling as evaluated by TOPflash activity.

To better define the role of porcupine in Wnt production in human PDAs, we transfected human PDAs with siRNA- specific for porcupine. Knockdown of porcupine protein was confirmed at 48 hours (Fig. 5A) and the supernatant was collected 24 hours later to determine efficacy of Wnts production by Western blot. Although we were able to knockdown greater than 90% of porcupine protein, Wnts 1, 3, 5b, and 10b were not inhibited by this remarkable reduction in porcupine expression (Fig. 5B, D–F). However, Wnt2b production was inhibited by porcupine knockdown by 60% in comparison to scrambled siRNA (Fig. 5C). We further confirmed these data in U138s transfected with TOPflash and siRNA for PORCN or scrambled siRNA. Knockdown of porcupine did not alter TOPflash activity in U138s (Fig. 6). These data indicate that porcupine is not necessary for production of most Wnt proteins from astrocytes or for β-catenin-mediated transcriptional activity elicited by Wnt ligands. Porcupine is necessary for production of Wnt 2b, but other Wnts are able to compensate for the loss of Wnt 2b thereby not altering β-catenin activity.

Discussion

We used both the small molecule IWP-2 discovered by Chen et al [10] and siRNA targeting porcupine to assess the impact of porcupine on Wnt ligand secretion in human primary astrocytes (PDAs and Hfas), an astrocytic cell line (U138), and primary human CD8+ T cells. We show through knockdown of porcupine that it is not required for the production of Wnt 1, 3, 5b, and 10b, but it was required for the release of Wnt 2b. Interestingly, IWP-2 molecule was not effective in inhibiting Wnt ligand release in these cells. The pathway of Wnt production and secretion is not fully elucidated. Studies focusing on Wnt secretion have been hampered by the fact that Wnt secretion and activity is necessary for normal development as inhibiting β-catenin activity results in an embryonic lethal phenotype. Additionally, dysregulation of Wnt secretion is linked to a host of disorders including cancer, cardiac pathophysiology, Alzheimer’s disease and others [1,3,22–25]. Therefore, methods of inhibiting Wnt secretion typically rely on pharmacologic agents (such as small molecule inhibitors) or genetic manipulation of the secretory pathway.
Porcupine has been identified as a key player of Wnt production in several mouse and drosophila studies. However, data regarding porcupine activity is conflicting. When porcupine is inhibited in vivo the outcome is a host of developmental disorders, most notably Goltz Syndrome which causes focal dermal hypoplasia. Conversely, when porcupine is overactive cancerous cell growth occurs [1,8,17,26]. Additionally, while porcupine has been shown to be necessary for the palmitoylation of Wnt 3a in mice it does not

Figure 2. IWP-2 does not inhibit production of Wnts from human astrocytes. PDAs were treated with 5 μM IWP-2 or vehicle (10 μM DMSO). Twenty-four hours later, the media was changed and the cells were treated again with 5 μM IWP-2 for two additional days. On the third day, the supernatant was collected and western blot was performed on 25 μl of supernatant to determine presence of Wnts 1 (A), 2b (B), 3(C), 5b (D), and 10b (E).

doi:10.1371/journal.pone.0092159.g002

Figure 3. IWP-2 does not inhibit Wnt production from primary human CD8+ T cells. CD8+ T cells were isolated from PBMCs from healthy donors by negative selection and subsequently activated with 1 μg each anti-CD3/anti-CD28 then propagated in presence of 100 units/ml IL-2 for three days. On the third day supernatant was collected and 25 μl was analyzed by western blot for presence of Wnt 1 (A), 3 (B), 6 (C), 7a (D), 10a (E), and 16a (F).

doi:10.1371/journal.pone.0092159.g003
Porcupine may have additional functions beyond modification of Wnts for production. Studies have recently shown that porcupine may “moonlight” in a Wnt independent pathway that regulates proliferation of cancerous cells. Covey et. al. showed that inducible knockdown of porcupine by several siRNAs lead to delayed growth of established MDA-MB231 cancers in mice [27]. There is increasing evidence that highly conserved proteins may perform multiple different functions utilizing the same protein domain. Porcupine is highly conserved and was initially found in drosophila. While it plays a role in production and activity of some Wnts, it may also have other roles in cellular processes.

**Figure 4.** Wnts secreted from HFAs treated with IWP-2 are functional. HFAs were treated with 5 μM IWP-2 or vehicle (10 μM DMSO). Twenty-four hours later, the media was replaced with cDMEM and HFAs were treated with 5 μM IWP-2 each day for 2 days or vehicle. PBMCs were isolated from a healthy donor and activated overnight with 1 μg each anti-CD3/anti-CD28 and 100 units/ml IL-2. PBMCs were then transfected with either TOPflash or FOPflash, a vector control. PBMCs were then cultured with supernatant from IWP-2 or DMSO treated HFAs (ACM). Three days later, β-catenin activity was determined by luciferase assay. Data is representative of three PBMC donors. *p<0.05.
doi:10.1371/journal.pone.0092159.g004

**Figure 5.** PORCN is not essential for Wnt production by PDAs. PDAs were transfected with smartpool ON TARGET plus siRNA specific for human porcupine or scrambled siRNA. Forty eight hours after transfection cells were lysed and analyzed by western blot to confirm knockdown of porcupine (A). Supernatant was collected from cells at 96 hours post-transfection and analyzed by western blot to determine production of Wnt ligands (B–F). Data is representative of three separate experiments, *p<0.05.
doi:10.1371/journal.pone.0092159.g005

**Figure 6.** β-catenin activity is not altered by porcupine in U138-MG Cells. U138 cells were transfected with either a scrambled siRNA and TOPflash or FOP, and either siRNA specific for porcupine and TOP flash or FOP. 72 hours later β-catenin activity was determined by luciferase assay. This was performed three times.
doi:10.1371/journal.pone.0092159.g006
Wnts, our data indicate that it is unnecessary for production and activity of Wnts 1, 3, 5b, and 10b in human astrocytes, and only effective in the production of Wnt 2b. Wnt2b is briefly expressed in the primitive streak during gastrulation and in several organs during development but appears to be redundant as mice lacking Wnt2b are viable, fertile and have a normal life span. In fact, only mice lacking both Wnt2 and Wnt2b display any phenotype [28,29]. Our data indicate that despite effective knockdown of porcupine and inhibition of Wnt2b in astrocytes, TOPFlash activity is not affected. This may be due to the redundant nature of Wnt ligands with Wnts 1, 3, 5b, and 10b promoting β-catenin activity in the absence of Wnt2b. How Wnt2b interacts with porcupine is currently unknown, however our data indicates that porcupine is necessary for Wnt2b production in human astrocytes and CD8+ T cells.

In order to fully elucidate the role of Wnt ligands we must be able to selectively inhibit their activity and production. A better understanding of the Wnt production pathway for each of the 19 known human Wnts is necessary before global inhibitors can be used. Our data and data from others indicate that different species may have developed redundant pathways for Wnt production that may vary from cell type to cell type. Further investigation of the Wnt secretory pathway in primary cells is necessary before the full impact of Wnts can be appreciated.

**Author Contributions**

Conceived and designed the experiments: MHR LA. Performed the experiments: MHR MSS JW. Analyzed the data: MHR LA. Wrote the paper: MHR LA.

---

**References**

1. Polak P (2007) The many ways of wnt in cancer. Curr Opin Genet Dev 17: 45–50.
2. Angers S, Moon RT (2009) Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 10: 468–477.
3. Coombs GS, Covey TM, Virshup DM (2008) Wnt signaling in development, disease and translational medicine. Curr Drug Targets 9: 513–531.
4. Hofmann K (2000) A superfamily of membrane-bound O-acetyltransferases with implications for Wnt signaling. Trends Biochem Sci 25: 111–112.
5. Galli LM, Burris LW (2011) Differential palmitoylation of Wnt1 on C93 and S224 residues has overlapping and distinct consequences in life. J Biol Chem 286: e02636.
6. Ching W, Hang HC, Nuse R (2008) Lipid-independent secretion of a drosophila wnt protein. J Biol Chem 283: 17092–17098.
7. Herr P, Baider K (2012) Porcupine-mediated lipidation is required for Wnt recognition by sfrp. Dev Biol 361: 392–402.
8. Herr P, Hausmann G, Baider K (2012) WNT signaling and secretion in human disease. Trends Mol Med 18: 483–493.
9. Tang X, Wu Y, Belenkaya TY, Huang Q, Roy L, et al. (2012) Roles of Nglycosylation and lipidation in Wnt secretory pathway. Dev Biol 364: 32–41.
10. Chen B, Dodge ME, Tang W, Lu J, Ma Z, et al. (2009) Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 5: 100–107.
11. Wang X, Moon J, Dodge ME, Pan X, Zhang L, et al. (2013) The development of highly potent inhibitors for porcupine. J Med Chem 56: 2700–2704.
12. Hadiyan K, Vincendeau M, Maasbacher N, Nagel D, Hauck SM, et al. (2009) Identification of a heterogenous nuclear ribonucleoprotein-recognition region in the HIV rev protein. J Biol Chem 284: 33384–33391.
13. Lamba S, Ravichandran V, Major EO (2009) Gial cell type-specific subcellular localization of 14-3-3 zeta: An implication for JCV tropism. Glia 57: 971–977.
14. Li W, Henderson LJ, Major EO, Al-Harthi L (2011) TβR-I mediates enhancement of HIV replication in astrocytes by inducing an antagonist of the β-catenin pathway (DKK1) in a STAT 3-dependent manner. J Immunol 186: 6771–6778.
15. Narasipura SD, Henderson LJ, Fu SW, Chen L, Kashanchi F, et al. (2012) Role of the porcupine gene and TGF/LIF family members in transcriptional activity of HIV in astrocytes. J Virol 86: 1911–1921.
16. Bierchele S, Cox BJ, Rossant J (2011) Porcupine homolog is required for canonical Wnt signaling and gastrulation in mouse embryos. Dev Biol 355: 273–285.
17. Barrett JJ, Cash GM, Smith AP, Barrows JR, Murtagh LC (2011) Deletion of mouse porcino blocks Wnt ligand secretion and reveals an ectodermal eutrophy of human focal dermal hyaloplasia/Goldz syndrome. Proc Natl Acad Sci U S A 108: 12752–12757.
18. Caricasole A, Ferraro T, Rimland JM, Terstappen GC (2002) Molecular cloning and initial characterization of the MG61/PORC gene, the human homologue of the drosophila segment polarity gene porcupine. Genes Dev 16: 147–157.
19. Galli LM, Barnes TL, Secrett SS, Kadwadi T, Burris LW (2007) Porcupine-mediated lipid-modification regulates the activity and distribution of Wnt proteins in the chick neural tube. Development 134: 3339–3346.
20. Takada R, Satomi Y, Kurata T, Ueno N, Norisaka S, et al. (2006) Mouse mutated fatty acid modification of wnt protein: Its role in Wnt secretion. Dev Cell 11: 791–801.
21. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, et al. (2003) Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423: 448–452.
22. Al-Harthi L (2012) Wnt/β-catenin and its diverse physiological cell signaling pathways in neurodegenerative and neuropsychiatric disorders. J Neuroimmune Pharmacol 7: 725–730.
23. Cerpa W, Toledo EM, Varela-Nallar L, Inestrosa NC (2009) The role of wnt signaling in neuroprotection. Drug News Perspect 22: 579–591.
24. Lancaster MA, Gleeson JG (2010) Cystic kidney disease: The role of wnt signaling. Trends Mol Med 16: 349–360.
25. Dawson K, Affaki M, Nattel S (2013) Role of the wnt-frizzled system in cardiac pathophysiology: A rapidly developing, poorly understood area with enormous potential. J Physiol 591: 1427–1432.
26. Gao X, Arezou-Ramezani N, Okabe SJ, Hannoush RN (2011) Membrane targeting of palmitoylated wnt and hedgehog revealed by chemical probes. FEBS Lett 585: 2501–2506.
27. Covey TM, Kaur S, Tan Ong T, Proffitt KD, Wu Y, et al. (2012) PORCN moonlights in a Wnt-independent pathway that regulates cancer cell proliferation. PLoS One 7: e34532.
28. Goss AM, Tian Y, Tsukiyama T, Cohen EZ, Zhou D, et al. (2009) Wnt2b and beta-catenin signaling are necessary and sufficient to specify lung progenitors in the foregut. Dev Cell 17: 290–298.
29. Tsukiyama T, Yamaguchi TP (2012) Mice lacking Wnt2b are viable and display a postnatal olfactory bulb phenotype. Neurosci Lett 512: 48–52.
30. Al-Harthi L (2012) Interplay between Wnt/β-catenin signaling and HIV: Virologic and biologic consequences in the CNS. J Neuroimmune Pharmacol 7: 731–739.
31. Kadwadi T, Wilder E, Kringelum J, Zachary K, Perrimon N (1996) The segment polarity gene porcupine encodes a putative multitransmembrane protein involved in wingless processing. Genes Dev 10: 316–328.
32. Kumar A, Zloza A, Moon RT, Watts J, Tenorio AR, et al. (2008) Active β-catenin signaling is an inhibitory pathway for human immunodeficiency virus replication in peripheral blood mononuclear cells. J Virol 82: 2013–2020.
33. Noweermer K, Kringelum J, Nuse R (1995) Differential requirements for segment polarity genes in wingless signaling. Mech Dev 51: 145–155.
34. Nuse R (2003) Wnts and hedgegogs: Lipid-modified proteins and similarities in signaling mechanisms at the cell surface. Development 130: 5297–5305.
35. Perrimon N, Engstrom L, Mahowald AP (1989) Zigotic lethals with specific maternal effect phenotypes in drosophila melanogaster. I. loci on the X chromosome. Genetics 121: 333–352.
36. Perrimon N, Mahowald AP (1987) Multiple functions of segment polarity genes in drosophila. Dev Biol 119: 387–400.
37. Siegfried E, Wilder EL, Perrimon N (1994) Components of wingless signalling in drosophila. Nature 367: 76–80.
38. Tagaka T, Kistagawa Y, Kadwadi T (2002) Drosophila segment polarity gene product porcupine stimulates the posttranslational N-glycosylation of wingless in the mouse models. Mol Pharmacol 7: 3116–3128.
39. Tagaka T, Okabayashi K, Asahima M, Perrimon N, Kadwadi T (2008) The evolutionarily conserved porcupine gene family is involved in the processing of the wnt family. Eur J Biochem 267: 4300–4311.
40. van de Hey HE, Herryman-Samos C, Kringelum J, Perrimon N, Nuse R (1993) Mutations in the segment polarity genes wingles and porcupine impair secretion of the wingless protein. EMBO J 12: 5293–5302.
41. Zhai L, Chaturvedi D, Cumberledge S (2004) Drosophila wnt-1 undergoes a hydrophobic modification and is targeted to lipid rafts, a process that requires porcupine. J Biol Chem 279: 35220–35227.